Megakaryocyte modification of platelets in thrombocytopenia

[thumbnail of 2018_Roweth_Megakaryocyte modification of platelets in thrombocytopenia.pdf]
Text
· Restricted to Repository staff only
· The Copyright of this document has not been checked yet. This may affect its availability.

Please see our End User Agreement.

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

Add to AnyAdd to TwitterAdd to FacebookAdd to LinkedinAdd to PinterestAdd to Email

Roweth, H. G. ORCID: https://orcid.org/0000-0002-1100-8409, Parvin, S. and Machlus, K. R. ORCID: https://orcid.org/0000-0002-2155-1050 (2018) Megakaryocyte modification of platelets in thrombocytopenia. Current opinion in hematology, 25 (5). pp. 410-415. ISSN 1531-7048 doi: 10.1097/moh.0000000000000451

Abstract/Summary

<h4>Purpose of review</h4>Platelets are small, anucleate cells that circulate within the blood and play essential roles in preserving vascular integrity. However, abnormalities in either platelet production or destruction can result in thrombocytopenia, clinically defined by a platelet count lower than 150 000/μL of whole blood. Thrombocytopenia is frequently associated with impaired hemostatic responses to vascular injury and can be life-threatening because of bleeding complications. Megakaryocytes are the precursor cells responsible for platelet production, a process commonly referred to as thrombopoiesis. This review specifically discusses how perturbation of molecular mechanisms governing megakaryocyte differentiation and development manifest in various forms of thrombocytopenia.<h4>Recent findings</h4>This review highlights the identification of novel transcriptional regulators of megakaryocyte maturation and platelet production. We also provide an update into the essential role of cytoskeletal regulation in thrombopoiesis, and how both megakaryopoiesis and platelet production are altered by anticancer therapeutics. Lastly, we focus on recent investigative approaches to treat thrombocytopenia and discuss future prospects in the field of megakaryocyte research.<h4>Summary</h4>In patients where thrombocytopenia is not due to heightened platelet destruction or clearance, defects in megakaryocyte development should be considered.

Altmetric Badge

Dimensions Badge

Item Type Article
URI https://centaur.reading.ac.uk/id/eprint/127730
Identification Number/DOI 10.1097/moh.0000000000000451
Refereed Yes
Divisions No Reading authors. Back catalogue items
Publisher Lippincott, Williams & Wilkins
Download/View statistics View download statistics for this item

University Staff: Request a correction | Centaur Editors: Update this record